REstart or STop Antithrombotic Randomised Trial in France
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
RESTART- fr is a randomised controlled trial for adults surviving spontaneous intracerebral
haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet
medication) for the prevention of vaso-occlusive disease before the ICH.
RESTART- fr is testing whether a policy of starting antiplatelet drugs (one or more of
aspirin, clopidogrel, or dipyridamole, chosen at investigator's discretion) results in a
beneficial net reduction of all serious vascular events over two years compared with a policy
of avoiding antiplatelet drugs.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Lille
Collaborators:
Ministry of Health, France Région Hauts de France, France